To investigate individual patient data from a comprehensive trials programme to evaluate the safety and efficacy of the dipeptidyl peptidase-@ ( DPP-@ ) inhibitor linagliptin across a range of glucose-lowering regimens in a large elderly population with type @ diabetes mellitus ( T@DM ) .